A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy
- 1 December 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 267, 181-190
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (20100027955, 2015R1A2A2A05001390, 2013M3A9D3045881, 2014R1A2A1A10054205)
This publication has 43 references indexed in Scilit:
- PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivoBiomaterials, 2011
- Efficient delivery of DNA vaccines using human papillomavirus pseudovirionsGene Therapy, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Emerging applications of stimuli-responsive polymer materialsNature Materials, 2010
- Self-assembled hyaluronic acid nanoparticles for active tumor targetingBiomaterials, 2010
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Temperature-Sensitive Hybrid Microgels with Magnetic PropertiesLangmuir, 2004
- Lymphocyte-Mediated CytotoxicityAnnual Review of Immunology, 2002
- MHC Class I–Restricted CTL Responses to Exogenous AntigensImmunity, 1996